Intratumoral Cancer Therapies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major intratumoral cancer therapies markets reached a value of US$ 148.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 303.4 Billion by 2034, exhibiting a growth rate (CAGR) of 6.72% during 2024-2034.
The intratumoral cancer therapies market has been comprehensively analyzed in IMARC's new report titled "Intratumoral Cancer Therapies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Intratumoral cancer therapies are a type of cancer treatment that involves the direct injection of drugs into a tumor. These therapies deliver high concentrations of therapeutic agents directly to the tumor site, reducing the risk of damage to healthy tissues and organs. Additionally, intratumoral therapies can be tailored to target specific mutations and genetic markers in a patient's tumor, offering the potential for more effective treatments. These medicaments can be delivered through a variety of methods, such as injection, implantation, infusion, etc. The therapeutic agents used in the procedures can include chemotherapy drugs, immunotherapy agents, or targeted therapies. Intratumoral cancer therapies are particularly useful in cases where the tumor is difficult to access or when systemic chemotherapy or radiation therapy is not effective. They can also be combined with other therapeutic interventions, such as immunotherapy or targeted therapy, to provide a more comprehensive approach to cancer treatment.
The rising prevalence of cancer and the escalating demand for therapies that can deliver drugs or other therapeutic agents directly to the tumor site, allowing for targeted treatment, are primarily driving the intratumoral cancer therapies market. Furthermore, the increasing utilization of these medicaments for treating cancers that have become resistant to conventional therapeutic procedures is acting as another significant growth-inducing factor. For instance, oncolytic virus therapy can stimulate the immune system to attack cancer cells, potentially overcoming immune evasion mechanisms that may contribute to treatment resistance. Apart from this, the widespread adoption of immunotherapy drugs which can be customized based on the patient's genetic profile and tailored to their individual needs to improve outcomes, is further creating a positive outlook for the market. Moreover, several regulatory agencies are introducing favorable policies, such as streamlining the approval process, to support the development and commercialization of intratumoral cancer therapies. This, in turn, is also propelling the market growth. Additionally, the emerging popularity of intratumoral cancer treatments that can be delivered using minimally invasive techniques, including ultrasound-guided injections, thereby reducing the need for surgery, is expected to drive the intratumoral cancer therapies market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the intratumoral cancer therapies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for intratumoral cancer therapies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the intratumoral cancer therapies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the intratumoral cancer therapies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the intratumoral cancer therapies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current intratumoral cancer therapies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the intratumoral cancer therapies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the intratumoral cancer therapies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the intratumoral cancer therapies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of intratumoral cancer therapies across the seven major markets?
What is the number of prevalent cases (2018-2034) of intratumoral cancer therapies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of intratumoral cancer therapies by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of intratumoral cancer therapies by type across the seven major markets?
How many patients are diagnosed (2018-2034) with intratumoral cancer therapies across the seven major markets?
What is the size of the intratumoral cancer therapies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of intratumoral cancer therapies?
What will be the growth rate of patients across the seven major markets?
Intratumoral Cancer Therapies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for intratumoral cancer therapies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the intratumoral cancer therapies market?
What are the key regulatory events related to the intratumoral cancer therapies market?
What is the structure of clinical trial landscape by status related to the intratumoral cancer therapies market?
What is the structure of clinical trial landscape by phase related to the intratumoral cancer therapies market?
What is the structure of clinical trial landscape by route of administration related to the intratumoral cancer therapies market?
The intratumoral cancer therapies market has been comprehensively analyzed in IMARC's new report titled "Intratumoral Cancer Therapies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Intratumoral cancer therapies are a type of cancer treatment that involves the direct injection of drugs into a tumor. These therapies deliver high concentrations of therapeutic agents directly to the tumor site, reducing the risk of damage to healthy tissues and organs. Additionally, intratumoral therapies can be tailored to target specific mutations and genetic markers in a patient's tumor, offering the potential for more effective treatments. These medicaments can be delivered through a variety of methods, such as injection, implantation, infusion, etc. The therapeutic agents used in the procedures can include chemotherapy drugs, immunotherapy agents, or targeted therapies. Intratumoral cancer therapies are particularly useful in cases where the tumor is difficult to access or when systemic chemotherapy or radiation therapy is not effective. They can also be combined with other therapeutic interventions, such as immunotherapy or targeted therapy, to provide a more comprehensive approach to cancer treatment.
The rising prevalence of cancer and the escalating demand for therapies that can deliver drugs or other therapeutic agents directly to the tumor site, allowing for targeted treatment, are primarily driving the intratumoral cancer therapies market. Furthermore, the increasing utilization of these medicaments for treating cancers that have become resistant to conventional therapeutic procedures is acting as another significant growth-inducing factor. For instance, oncolytic virus therapy can stimulate the immune system to attack cancer cells, potentially overcoming immune evasion mechanisms that may contribute to treatment resistance. Apart from this, the widespread adoption of immunotherapy drugs which can be customized based on the patient's genetic profile and tailored to their individual needs to improve outcomes, is further creating a positive outlook for the market. Moreover, several regulatory agencies are introducing favorable policies, such as streamlining the approval process, to support the development and commercialization of intratumoral cancer therapies. This, in turn, is also propelling the market growth. Additionally, the emerging popularity of intratumoral cancer treatments that can be delivered using minimally invasive techniques, including ultrasound-guided injections, thereby reducing the need for surgery, is expected to drive the intratumoral cancer therapies market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the intratumoral cancer therapies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for intratumoral cancer therapies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the intratumoral cancer therapies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the intratumoral cancer therapies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the intratumoral cancer therapies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current intratumoral cancer therapies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the intratumoral cancer therapies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the intratumoral cancer therapies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the intratumoral cancer therapies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of intratumoral cancer therapies across the seven major markets?
What is the number of prevalent cases (2018-2034) of intratumoral cancer therapies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of intratumoral cancer therapies by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of intratumoral cancer therapies by type across the seven major markets?
How many patients are diagnosed (2018-2034) with intratumoral cancer therapies across the seven major markets?
What is the size of the intratumoral cancer therapies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of intratumoral cancer therapies?
What will be the growth rate of patients across the seven major markets?
Intratumoral Cancer Therapies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for intratumoral cancer therapies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the intratumoral cancer therapies market?
What are the key regulatory events related to the intratumoral cancer therapies market?
What is the structure of clinical trial landscape by status related to the intratumoral cancer therapies market?
What is the structure of clinical trial landscape by phase related to the intratumoral cancer therapies market?
What is the structure of clinical trial landscape by route of administration related to the intratumoral cancer therapies market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRATUMORAL CANCER THERAPIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INTRATUMORAL CANCER THERAPIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INTRATUMORAL CANCER THERAPIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 INTRATUMORAL CANCER THERAPIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INTRATUMORAL CANCER THERAPIES - UNMET NEEDS
10 INTRATUMORAL CANCER THERAPIES - KEY ENDPOINTS OF TREATMENT
11 INTRATUMORAL CANCER THERAPIES - MARKETED PRODUCTS
11.1 List of Intratumoral Cancer Therapies Marketed Drugs Across the Top 7 Markets
11.1.1 Imlygic (Talimogene laherparepvec) - Amgen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Hensify (Hafnium oxide) - Nanobiotix
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Delytact (Teserpaturev) - Daiichi Sankyo
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 INTRATUMORAL CANCER THERAPIES - PIPELINE DRUGS
12.1 List of Intratumoral Cancer Therapies Pipeline Drugs Across the Top 7 Markets
12.1.1 CMP-001 - Checkmate Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NanoPac - DFB Soria/NanOlogy
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Tavo - OncoSec Medical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 LOAd703 - Lokon Pharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 PVSRIPO - Istari Oncology
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. INTRATUMORAL CANCER THERAPIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INTRATUMORAL CANCER THERAPIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INTRATUMORAL CANCER THERAPIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Intratumoral Cancer Therapies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Intratumoral Cancer Therapies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Intratumoral Cancer Therapies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Intratumoral Cancer Therapies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Intratumoral Cancer Therapies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Intratumoral Cancer Therapies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Intratumoral Cancer Therapies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Intratumoral Cancer Therapies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
16 INTRATUMORAL CANCER THERAPIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INTRATUMORAL CANCER THERAPIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INTRATUMORAL CANCER THERAPIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRATUMORAL CANCER THERAPIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INTRATUMORAL CANCER THERAPIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INTRATUMORAL CANCER THERAPIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 INTRATUMORAL CANCER THERAPIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INTRATUMORAL CANCER THERAPIES - UNMET NEEDS
10 INTRATUMORAL CANCER THERAPIES - KEY ENDPOINTS OF TREATMENT
11 INTRATUMORAL CANCER THERAPIES - MARKETED PRODUCTS
11.1 List of Intratumoral Cancer Therapies Marketed Drugs Across the Top 7 Markets
11.1.1 Imlygic (Talimogene laherparepvec) - Amgen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Hensify (Hafnium oxide) - Nanobiotix
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Delytact (Teserpaturev) - Daiichi Sankyo
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 INTRATUMORAL CANCER THERAPIES - PIPELINE DRUGS
12.1 List of Intratumoral Cancer Therapies Pipeline Drugs Across the Top 7 Markets
12.1.1 CMP-001 - Checkmate Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NanoPac - DFB Soria/NanOlogy
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Tavo - OncoSec Medical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 LOAd703 - Lokon Pharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 PVSRIPO - Istari Oncology
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. INTRATUMORAL CANCER THERAPIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INTRATUMORAL CANCER THERAPIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INTRATUMORAL CANCER THERAPIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Intratumoral Cancer Therapies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Intratumoral Cancer Therapies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Intratumoral Cancer Therapies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Intratumoral Cancer Therapies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Intratumoral Cancer Therapies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Intratumoral Cancer Therapies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Intratumoral Cancer Therapies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Intratumoral Cancer Therapies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Intratumoral Cancer Therapies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Intratumoral Cancer Therapies - Access and Reimbursement Overview
16 INTRATUMORAL CANCER THERAPIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INTRATUMORAL CANCER THERAPIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INTRATUMORAL CANCER THERAPIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
